References
- Bourbeau J, Bhutani M, Hernandez P, et al. 2023 Canadian thoracic society guideline on pharmacotherapy in patients with stable COPD. Can J Respir Crit Care Sleep Med. 2023;7(4):1–5. doi: 10.1080/24745332.2023.2231451.
- Bourbeau J, Bhutani M, Hernandez P, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. CHEST. 2023;164(5):1159–1183. doi: 10.1016/j.chest.2023.08.014.
- Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi: 10.1183/13993003.00239-2023.
- Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi: 10.1016/S2213-2600(18)30006-7.
- Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi: 10.1164/rccm.201502-0235LE.
- Singh D, Agusti A, Martinez FJ, et al. Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review. Am J Respir Crit Care Med. 2022;206(1):17–24. doi: 10.1164/rccm.202201-0209PP.
- Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi: 10.1164/rccm.201911-2207OC.
- Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi: 10.1164/rccm.202006-2618OC.
- Wedzicha J, Banerji D, Kostikas K. Single-Inhaler triple versus dual therapy in patients with COPD. New Eng J Med. 2018;379(6):590–593.
- Suissa S, Ariel A. Triple therapy in COPD: only for the right patient. Eur Respir J. 2019;53(4):1900394. doi: 10.1183/13993003.00394-2019.
- Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021;9(7):684–685.
- Suissa S, Ernst P, Benayoun B, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–336. doi: 10.1056/NEJM200008033430504.
- Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur Respir J. 2017;49(6):1700361. doi: 10.1183/13993003.00361-2017.
- Suissa S. Triple therapy in COPD: understanding the data. ERJ Open Res. 2023;9(1):00615–2022. doi: 10.1183/23120541.00615-2022.
- Food and Drug Administration Center for Drug Evaluation and Research. Final Summary Minutes of the Pulmonary-Allergy Drugs Advisory Committee Meeting; August 31, 2020 [cited 2023 Nov 08]. Available from: https://www.fda.gov/media/143921/download.
- U.S. Food and Drug Administration. Warning letter. AstraZeneca Pharmaceuticals LP; August 4, 2023 [cited 2023 Nov 08]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/astrazeneca-pharmaceuticals-lp-664789-08042023.
- Suissa S. Single-inhaler triple versus dual bronchodilator therapy for GOLD E and other exacerbating patients with COPD: real-world comparative effectiveness and safety. Eur Respir J. 2023;62(3):2300883. doi: 10.1183/13993003.00883-2023.